Key TakeawaysEli Lilly shares dropped more than 4% on Thursday as investors assessed the possible impact of a promising new weight-loss injection developed by Viking Therapeutics on the drugmaker’s own anti-obesity drug, Mounjaro.The stock's technicals, including bearish divergence and a decisive close beneath a multi-month uptrend line and the 50-day moving average, point to a potential reversal.Eli Lilly shares may encounter support on the chart from prior price action at $790, $725, and $625.A bars patte ...

Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%.Outside of the technology industry, investors have also found outsize gains among some opportunities in the pharmaceutical space. One company that has outpaced both the S&P 500 and Nasdaq since last January is Eli ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesEli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13.75 per share. Does this make the stock expensive? We don’t think so, considering that Eli Lilly’s revenues could grow over 75 ...

Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.It wasn't so long ago when Novo Nordisk (NVO -2.84%) and Eli Lilly (LLY -4.50%) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly).In the pharmaceutical industry, as in other sectors, a high-demand product encourages competitors to enter the same segment. News of a rapidly emerging rival put the hurt on both ...

Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.While a stock split does not change anything in terms of the fundamentals of the company, it makes it easier for investors to own the stock. 2024 has been the year for stock splits and there are many stock split candidates that could make the big announcement.Right from the tech darling Nvidia (NASDAQ:NVDA) to the popular Chipotle Mexican Grill (N ...

INDIANAPOLIS, July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://invest ...

jetcityimage One of the most amazing growth stories, especially if you ignore the semiconductor space, over the past couple of years, has been pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In just the past year, shares of the stock are up 88.5%. This comes on the back of tremendous growth driven by its weight loss drugs. As I detailed in a prior article, this has the potential to generate tremendous value for the company and its investors. But up until recently, the conversation has really only ...

Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are now at the forefront of medical advancements in weight management.GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in hum ...

Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.With Eli Lilly up by a stunning 47% so far this year, many investors are likely prone to feeling they're stuck on the sidelines after this bull run. Even if there's plenty of upside left -- and in Eli Lilly's case, there almost certainly is -- it can still feel safer to find another company that looks to have good times ahead rather than buying shares of yesterday's winner.There's no foolproof way of determining which bus ...

Key TakeawayEli Lilly announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.Tirzepatide is the active ingredient in Lilly’s injectable diabetes treatment Mounjaro and weight-loss drug Zepbound.Novo Nordisk announced in June that its weight-loss drug Wegovy received similar approval in China. Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide fo ...